Tumor suppression by p53: Making cells senescent

Histology and Histopathology

Volumn 25, Issue 4, 2010, Pages 515-526

  Qian, Yingjuan ^a   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cellular senescence; P21; P53; Tumor Suppression

Indexed keywords

PROTEIN P53;

ANIMAL; CELL AGING; DISEASE MODEL; GENE EXPRESSION REGULATION; MOUSE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CELL AGING; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 77950207196     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Afshari C.A., Nichols M.A., Xiong Y. and Mudryj M. (1996). A role for a p21-e2f interaction during senescence arrest of normal human fibroblasts. Cell. Growth Differ. 7, 979-988.
2. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B. and Stark G.R. (1998). The p53 network. J. Biol. Chem. 273, 1-4.
3. Alani R.M., Hasskarl J., Grace M., Hernandez M.C., Israel M.A. and Munger K. (1999). Immortalization of primary human keratinocytes by the helix-loop-helix protein, id-1. Proc. Natl. Acad. Sci. USA 96, 9637-9641.
4. Alexander K. and Hinds P.W. (2001). Requirement for p27(kip1) in retinoblastoma protein-mediated senescence. Mol. Cell. Biol. 21, 3616-3631.
5. Alexander K., Yang H.S. and Hinds P.W. (2003). Prb inactivation in senescent cells leads to an e2f-dependent apoptosis requiring p73. Mol. Cancer Res. 1, 716-728.
6. Andreasen P.A., Egelund R. and Petersen H.H. (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57, 25-40.
7. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Orntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J. and Gorgoulis V.G. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637.
8. Beausejour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P. and Campisi J. (2003). Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J. 22, 4212-4222.
9. Beitzinger M., Oswald C., Beinoraviciute-Kellner R. and Stiewe T. (2006). Regulation of telomerase activity by the p53 family member p73. Oncogene 25, 813-826.
10. Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H. and Pandolfi P.P. (2004). Pml regulates p53 stability by sequestering mdm2 to the nucleolus. Nat. Cell Biol. 6, 665-672.
11. Birch J.M., Alston R.D., McNally R.J., Evans D.G., Kelsey A.M., Harris M., Eden O.B. and Varley J.M. (2001). Relative frequency and morphology of cancers in carriers of germline tp53 mutations. Oncogene 20, 4621-4628.
12. Bischof O., Kirsh O., Pearson M., Itahana K., Pelicci P.G. and Dejean A. (2002). Deconstructing pml-induced premature senescence. EMBO J. 21, 3358-3369.
13. Blackburn E.H. (1984). The molecular structure of centromeres and telomeres. Annu. Rev. Biochem. 53, 163-194.
14. Bladier C., Wolvetang E.J., Hutchinson P., de Haan J.B. and Kola I. (1997). Response of a primary human fibroblast cell line to h2o2: Senescence-like growth arrest or apoptosis? Cell Growth Differ. 8, 589-598.
15. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S. and Wright W.E. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352.
16. Bond J.A., Wyllie F.S. and Wynford-Thomas D. (1994). Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 9, 1885-1889.
17. Borden K.L. (2002). Pondering the promyelocytic leukemia protein (pml) puzzle: Possible functions for pml nuclear bodies. Mol. Cell Biol. 22, 5259-5269.
18. Borlon C., Chretien A., Debacq-Chainiaux F. and Toussaint O. (2007). Transient increased extracellular release of h2o2 during establishment of uvb-induced premature senescence. Ann. NY Acad. Sci. 1119, 72-77.
19. Bos J.L. (1989). Ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689.
20. Boudjelal M., Taneja R., Matsubara S., Bouillet P., Dolle P. and Chambon P. (1997). Overexpression of stra13, a novel retinoic acid-inducible gene of the basic helix-loop-helix family, inhibits mesodermal and promotes neuronal differentiation of p19 cells. Genes Dev. 11, 2052-2065.
21. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., Saville M.K. and Lane D.P. (2005). P53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19, 2122-2137.
22. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dorken B., Jenuwein T. and Schmitt C.A. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665.
23. Brown J.P., Wei W. and Sedivy J.M. (1997). Bypass of senescence after disruption of p21cip1/waf1 gene in normal diploid human fibroblasts. Science 277, 831-834.
24. Caelles C., Helmberg A. and Karin M. (1994). P53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220-223.
25. Campisi J. (2005). Suppressing cancer: The importance of being senescent. Science 309, 886-887.
26. Castro M.E., del Valle Guijarro M., Moneo V. and Carnero A. (2004). Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J. Cell Biochem. 92, 514-524.
27. Chang B.D., Xuan Y., Broude E.V., Zhu H., Schott B., Fang J. and Roninson I.B. (1999a). Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808-4818.
28. Chang B.D., Broude E.V., Dokmanovic M., Zhu H., Ruth A., Xuan Y., Kandel E.S., Lausch E., Christov K. and Roninson I.B. (1999b). A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59, 3761-3767.
29. Chen Q. and Ames B.N. (1994). Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast f65 cells. Proc. Natl. Acad. Sci. USA 91, 4130-4134.
30. Chintala S.K., Fueyo J., Gomez-Manzano C., Venkaiah B., Bjerkvig R., Yung W.K., Sawaya R., Kyritsis A.P. and Rao J.S. (1997). Adenovirus-mediated p16/cdkn2 gene transfer suppresses glioma invasion in vitro. Oncogene 15, 2049-2057.
31. Collado M., Medema R.H., Garcia-Cao I., Dubuisson M.L., Barradas M., Glassford J., Rivas C., Burgering B.M., Serrano M. and Lam E.W. (2000). Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27kip1. J. Biol. Chem. 275, 21960-21968.
32. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguria A., Zaballos A., Flores J.M., Barbacid M., Beach D. and Serrano M. (2005). Tumour biology: Senescence in premalignant tumours. Nature 436, 642.
33. Courtois S., de Fromentel C.C. and Hainaut P. (2004). P53 protein variants: Structural and functional similarities with p63 and p73 isoforms. Oncogene 23, 631-638.
34. Courtois S., Verhaegh G., North S., Luciani M.G., Lassus P., Hibner U., Oren M. and Hainaut P. (2002). Deltan-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21, 6722-6728.
35. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P. and Jackson S.P. (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198.
36. Dai C.Y. and Enders G.H. (2000). P16 ink4a can initiate an autonomous senescence program. Oncogene 19, 1613-1622.
37. de Stanchina E., Querido E., Narita M., Davuluri R.V., Pandolfi P.P., Ferbeyre G. and Lowe S.W. (2004). Pml is a direct p53 target that modulates p53 effector functions. Mol. Cell. 13, 523-535.
38. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre M., Nuciforo P.G., Bensimon A., Maestro R., Pelicci P.G. and d'Adda di Fagagna F. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyperreplication. Nature 444, 638-642.
39. Dimri G.P. (2005). What has senescence got to do with cancer? Cancer Cell. 7, 505-512.
40. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O. and et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92, 9363-9367.
41. Dohn M., Zhang S. and Chen X. (2001). P63alpha and deltanp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20, 3193-3205.
42. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Jr., Butel J.S. and Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
43. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W. and Vogelstein B. (1992). Definition of a consensus binding site for p53. Nat. Genet. 1, 45-49.
44. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W. and Vogelstein B. (1993). Waf1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
45. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., Wiman K.G., Mercer W.E., Kastan M.B., Kohn K.W., Elledge S.J., Kinzler K.W. and Wogelstein B. (1994). Waf1/cip1 is induced in p53-mediated g1 arrest and apoptosis. Cancer Res. 54, 1169-1174.
46. Elmore L.W., Rehder C.W., Di X., McChesney P.A., Jackson-Cook C.K., Gewirtz D.A. and Holt S.E. (2002). Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 277, 35509-35515.
47. Farrell N., Povirk L.F., Dange Y., DeMasters G., Gupta M.S., Kohlhagen G., Khan Q.A., Pommier Y. and Gewirtz D.A. (2004). Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human a2780 ovarian and mcf-7 breast carcinoma cells. Biochem. Pharmacol. 68, 857-866.
48. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C. and Lowe S.W. (2000). Pml is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015-2027.
49. Ferbeyre G., de Stanchina E., Lin A.W., Querido E., McCurrach M.E., Hannon G.J. and Lowe S.W. (2002). Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell Biol. 22, 3497-3508.
50. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F. and Jacks T. (2002). P63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564.
51. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., Yang A., McKeon F. and Jacks T. (2005). Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 7, 363-373.
52. Gasco M., Yulug I.G. and Crook T. (2003). Tp53 mutations in familial breast cancer: Functional aspects. Hum. Mutat 21, 301-306.
53. Gorbunova V., Seluanov A. and Pereira-Smith O.M. (2002). Expression of human telomerase (htert) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J Biol Chem 277, 38540-38549.
54. Halazonetis T.D., Gorgoulis V.G. and Bartek J. (2008). An oncogeneinduced DNA damage model for cancer development. Science 319, 1352-1355.
55. Han Z., Wei W., Dunaway S., Darnowski J.W., Calabresi P., Sedivy J., Hendrickson E.A., Balan K.V., Pantazis P. and Wyche J.H. (2002). Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277, 17154-17160.
56. Hansen R. and Oren M. (1997). P53; from inductive signal to cellular effect. Curr. Opin. Genet Dev. 7, 46-51.
57. Hara E., Yamaguchi T., Nojima H., Ide T., Campisi J., Okayama H. and Oda K. (1994). Id-related genes encoding helix-loop-helix proteins are required for g1 progression and are repressed in senescent human fibroblasts. J. Biol. Chem. 269, 2139-2145.
58. Harley C.B., Futcher A.B. and Greider C.W. (1990). Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460.
59. Harms K., Nozell S. and Chen X. (2004). The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci. 61, 822-842.
60. Harris S.L. and Levine A.J. (2005). The p53 pathway: Positive and negative feedback loops. Oncogene 24, 2899-2908.
61. Hayflick L. (1965). The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614-636.
62. Hayflick L. and Moorhead P.S. (1961). The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585-621.
63. Herbig U., Jobling W.A., Chen B.P., Chen D.J. and Sedivy J.M. (2004). Telomere shortening triggers senescence of human cells through a pathway involving atm, p53, and p21(cip1), but not p16(ink4a). Mol. Cell. 14, 501-513.
64. Hofseth L.J., Hussain S.P. and Harris C.C. (2004). P53: 25 years after its discovery. Trends Pharmacol. Sci. 25, 177-181.
65. Honma S., Kawamoto T., Takagi Y., Fujimoto K., Sato F., Noshiro M., Kato Y. and Honma K. (2002). Dec1 and dec2 are regulators of the mammalian molecular clock. Nature 419, 841-844.
66. Itahana K., Dimri G. and Campisi J. (2001). Regulation of cellular senescence by p53. Eur. J. Biochem. 268, 2784-2791.
67. Itahana K., Zou Y., Itahana Y., Martinez J.L., Beausejour C., Jacobs J.J., Van Lohuizen M., Band V., Campisi J. and Dimri G.P. (2003). Control of the replicative life span of human fibroblasts by p16 and the polycomb protein bmi-1. Mol. Cell Biol. 23, 389-401.
68. Jackson J.G. and Pereira-Smith O.M. (2006). P53 is preferentially recruited to the promoters of growth arrest genes p21 and gadd45 during replicative senescence of normal human fibroblasts. Cancer Res. 66, 8356-8360.
69. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F. and Caput D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819.
70. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G. and Sherr C.J. (1997). Tumor suppression at the mouse ink4a locus mediated by the alternative reading frame product p19arf. Cell 91, 649-659.
71. Kanaya T., Kyo S., Hamada K., Takakura M., Kitagawa Y., Harada H. and Inoue M. (2000). Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 6, 1239-1247.
72. Kapic A., Helmbold H., Reimer R., Klotzsche O., Deppert W. and Bohn W. (2006). Cooperation between p53 and p130(rb2) in induction of cellular senescence. Cell Death Differ 13, 324-334.
73. Karlseder J., Smogorzewska A. and de Lange T. (2002). Senescence induced by altered telomere state, not telomere loss. Science 295, 2446-2449.
74. Karnoub A.E. and Weinberg R.A. (2008). Ras oncogenes: Split personalities. Nat. Rev. Mol. Cell. Biol. 9, 517-531.
75. Kemp C.J., Donehower L.A., Bradley A. and Balmain A. (1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813-822.
76. Keyes W.M. and Mills A.A. (2006). P63: A new link between senescence and aging. Cell Cycle 5, 260-265.
77. Keyes W.M., Wu Y., Vogel H., Guo X., Lowe S.W. and Mills A.A. (2005). P63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19, 1986-1999.
78. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A. and Klingelhutz A.J. (1998). Both rb/p16ink4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84-88.
79. Ko L.J. and Prives C. (1996). P53: Puzzle and paradigm. Genes Dev. 10, 1054-1072.
80. Kortlever R.M., Higgins P.J. and Bernards R. (2006). Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 8, 877-884.
81. Kunz C., Pebler S., Otte J. and von der Ahe D. (1995). Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 23, 3710-3717.
82. Kurz D.J., Decary S., Hong Y. and Erusalimsky J.D. (2000). Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell. Sci. 113, 3613-3622.
83. Land H., Parada L.F. and Weinberg R.A. (1983). Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602.
84. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G. and Kouzarides T. (2002). Human sir2 deacetylates p53 and antagonizes pml/p53-induced cellular senescence. EMBO J. 21, 2383-2396.
85. Le Gall J.Y., Khoi T.D., Glaise D., Le treut A., Brissot P. and Guillouzo A. (1979). Lysosomal enzyme activities during ageing of adult human liver cell lines. Mech. Ageing Dev. 11, 287-293.
86. Lee A.C., Fenster B.E., Ito H., Takeda K., Bae N.S., Hirai T., Yu Z.X., Ferrans V.J., Howard B.H. and Finkel T. (1999). Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem. 274, 7936-7940.
87. Lee B.Y., Han J.A., Im J.S., Morrone A., Johung K., Goodwin E.C., Kleijer W.J., DiMaio D. and Hwang E.S. (2006). Senescenceassociated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 5, 187-195.
88. Lehmann B.D., Brooks A.M., Paine M.S., Chappell W.H., McCubrey J.A. and Terrian D.M. (2008). Distinct roles for p107 and p130 in rbindependent cellular senescence. Cell Cycle 7, 1262-1268.
89. Levine A.J., Hu W. and Feng Z. (2006). The p53 pathway: What questions remain to be explored? Cell Death Differ. 13, 1027-1036.
90. Li F.P. and Fraumeni J.F., Jr. (1969). Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747-752.
91. Li R., Waga S., Hannon G.J., Beach D. and Stillman B. (1994). Differential effects by the p21 cdk inhibitor on pcna-dependent DNA replication and repair. Nature 371, 534-537.
92. Li Y., Xie M., Song X., Gragen S., Sachdeva K., Wan Y. and Yan B. (2003). Dec1 negatively regulates the expression of dec2 through binding to the e-box in the proximal promoter. J. Biol. Chem. 278, 16899-16907.
93. Li Y., Zhang H., Xie M., Hu M., Ge S., Yang D., Wan Y. and Yan B. (2002). Abundant expression of dec1/stra13/sharp2 in colon carcinoma: Its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation. Biochem. J. 367, 413-422.
94. Liu L.F., Desai S.D., Li T.K., Mao Y., Sun M. and Sim S.P. (2000). Mechanism of action of camptothecin. Ann. NY Acad. Sci. 922, 1-10.
95. Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P. and Haupt Y. (2003). The promyelocytic leukemia protein protects p53 from mdm2-mediated inhibition and degradation. J. Biol. Chem. 278, 33134-33141.
96. Lundblad V. and Szostak J.W. (1989). A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 57, 633-643.
97. Maier B., Gluba W., Bernier B., Turner T., Mohammad K., Guise T., Sutherland A., Thorner M. and Scrable H. (2004). Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306-319.
98. Mallette F.A. and Ferbeyre G. (2007). The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6, 1831-1836.
99. Mallette F.A., Gaumont-Leclerc M.F. and Ferbeyre G. (2007). The DNA damage signaling pathway is a critical mediator of oncogeneinduced senescence. Genes Dev. 21, 43-48.
100. Martins C.P., Brown-Swigart L. and Evan G.I. (2006). Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334.
101. Mills A.A., Zheng B., Wang X.J., Vogel H., Roop D.R. and Bradley A. (1999). P63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708-713.
102. Minden A., Lin A., McMahon M., Lange-Carter C., Derijard B., Davis R.J., Johnson G.L. and Karin M. (1994). Differential activation of erk and jnk mitogen-activated protein kinases by raf-1 and mekk. Science 266, 1719-1723.
103. Miyazaki K., Kawamoto T., Tanimoto K., Nishiyama M., Honda H. and Kato Y. (2002). Identification of functional hypoxia response elements in the promoter region of the dec1 and dec2 genes. J. Biol. Chem. 277, 47014-47021.
104. Moll U.M. and Slade N. (2004). P63 and p73: Roles in development and tumor formation. Mol. Cancer Res. 2, 371-386.
105. Mowat M., Cheng A., Kimura N., Bernstein A. and Benchimol S. (1985). Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by friend virus. Nature 314, 633-636.
106. Mu X.C. and Higgins P.J. (1995). Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent imr-90 human diploid fibroblasts. J. Cell Physiol. 165, 647-657.
107. Nakamura Y. (2004). Isolation of p53-target genes and their functional analysis. Cancer Sci. 95, 7-11.
108. Nelson W.G. and Kastan M.B. (1994). DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14, 1815-1823.
109. Nickoloff B.J., Chaturvedi V., Bacon P., Qin J.Z., Denning M.F. and Diaz M.O. (2000). Id-1 delays senescence but does not immortalize keratinocytes. J Biol Chem 275, 27501-27504.
110. Nijjar T., Wigington D., Garbe J.C., Waha A., Stampfer M.R. and Yaswen P. (1999). P57kip2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Res. 59, 5112-5118.
111. Noda A., Ning Y., Venable S.F., Pereira-Smith O.M. and Smith J.R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211, 90-98.
112. Norton J.D. (2000). Id helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J. Cell. Sci. 113, 3897-3905.
113. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C. and Hainaut P. (2002). The iarc tp53 database: New online mutation analysis and recommendations to users, Vol.19, Hum Mutat. pp. 607-614.
114. Pandita T.K. (2002). Atm function and telomere stability. Oncogene 21, 611-618.
115. Pantoja C. and Serrano M. (1999). Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic ras. Oncogene 18, 4974-4982.
116. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P. and Pelicci P.G. (2000). Pml regulates p53 acetylation and premature senescence induced by oncogenic ras. Nature 406, 207-210.
117. Prives C. and Hall P.A. (1999). The p53 pathway. J . Pathol. 187, 112-126.
118. Prives C. and Manfredi J.J. (2005). The continuing saga of p53-more sleepless nights ahead. Mol. Cell. 19, 719-721.
119. Qian Y. and Chen X. (2008). Id1, inhibitor of differentiation/DNA binding, is an effector of the p53-dependent DNA damage response pathway. J. Biol. Chem. 283, 22410-22416.
120. Qian Y., Zhang J., Yan B. and Chen X. (2008). Dec1, a basic helix-loophelix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J. Biol. Chem. 283, 2896-2905.
121. Racek T., Mise N., Li Z., Stoll A. and Putzer B.M. (2005). C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (htert) promoter. J. Biol. Chem. 280, 40402-40405.
122. Reedijk J. and Lohman P.H. (1985). Cisplatin: Synthesis, antitumour activity and mechanism of action. Pharm. Weekbl. Sci. 7, 173-180.
123. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G. and Ballabio A. (2001). The tripartite motif family identifies cell compartments. EMBO J. 20, 2140-2151.
124. Robles S.J., Buehler P.W., Negrusz A. and Adami G.R. (1999). Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin. Biochem. Pharmacol. 58, 675-685.
125. Roninson I.B. (2003). Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705-2715.
126. Rovinski B. and Benchimol S. (1988). Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2, 445-452.
127. Rovinski B., Munroe D., Peacock J., Mowat M., Bernstein A. and Benchimol S. (1987). Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: A novel mechanism of oncogene regulation. Mol. Cell Biol. 7, 847-853.
128. Ruley H.E. (1983). Adenovirus early region 1a enables viral and cellular transforming genes to transform primary cells in culture. Nature 304, 602-606.
129. Sabbatini P., Lin J., Levine A.J. and White E. (1995). Essential role for p53-mediated transcription in e1a-induced apoptosis. Genes Dev. 9, 2184-2192.
130. Schmale H. and Bamberger C. (1997). A novel protein with strong homology to the tumor suppressor p53. Oncogene 15, 1363-1367.
131. Schmitt C.A. (2007). Cellular senescence and cancer treatment. Biochim Biophys Acta 1775, 5-20.
132. Senoo M., Manis J.P., Alt F.W. and McKeon F. (2004). P63 and p73 are not required for the development and p53-dependent apoptosis of t cells. Cancer Cell 6, 85-89.
133. Serrano M., Lin A.W., McCurrach M.E., Beach D. and Lowe S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16ink4a. Cell 88, 593-602.
134. Shats I., Milyavsky M., Tang X., Stambolsky P., Erez N., Brosh R., Kogan I., Braunstein I., Tzukerman M., Ginsberg D. and Rotter V. (2004). P53-dependent down-regulation of telomerase is mediated by p21waf1. J. Biol. Chem. 279, 50976-50985.
135. Shen M., Kawamoto T., Yan W., Nakamasu K., Tamagami M., Koyano Y., Noshiro M. and Kato Y. (1997). Molecular characterization of the novel basic helix-loop-helix protein dec1 expressed in differentiated human embryo chondrocytes. Biochem. Biophys. Res. Commun. 236, 294-298.
136. Shen M., Yoshida E., Yan W., Kawamoto T., Suardita K., Koyano Y., Fujimoto K., Noshiro M. and Kato Y. (2002). Basic helix-loop-helix protein dec1 promotes chondrocyte differentiation at the early and terminal stages. J. Biol. Chem. 277, 50112-50120.
137. Sherwood S.W., Rush D., Ellsworth J.L. and Schimke R.T. (1988). Defining cellular senescence in imr-90 cells: A flow cytometric analysis. Proc. Natl. Acad. Sci. USA 85, 9086-9090.
138. Smogorzewska A. and de Lange T. (2002). Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21, 4338-4348.
139. St-Pierre B., Flock G., Zacksenhaus E. and Egan S.E. (2002). Stra13 homodimers repress transcription through class b e-box elements. J. Biol. Chem. 277, 46544-46551.
140. Stiewe T. and Putzer B.M. (2000). Role of the p53-homologue p73 in e2f1-induced apoptosis. Nat. Genet. 26, 464-469.
141. Sugrue M.M., Shin D.Y., Lee S.W. and Aaronson S.A. (1997). Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA 94, 9648-9653.
142. Sun H. and Taneja R. (2000). Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (hdac)-dependent and hdac-independent mechanisms. Proc. Natl. Acad. Sci. USA 97, 4058-4063.
143. Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R., 3rd, Wright P.E. and Han J. (2007). Prak is essential for ras-induced senescence and tumor suppression. Cell 128, 295-308.
144. Takai H., Smogorzewska A. and de Lange T. (2003). DNA damage foci at dysfunctional telomeres. Curr. Biol. 13, 1549-1556.
145. te Poele R.H., Okorokov A.L., Jardine L., Cummings J. and Joel S.P. (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62, 1876-1883.
146. Tiemann F. and Hinds P.W. (1998). Induction of DNA synthesis and apoptosis by regulated inactivation of a temperature-sensitive retinoblastoma protein. EMBO J. 17, 1040-1052.
147. Toh W.H., Kyo S. and Sabapathy K. (2005). Relief of p53-mediated telomerase suppression by p73. J. Biol. Chem 280, 17329-17338.
148. Toledo L.I., Murga M., Gutierrez-Martinez P., Soria R. and Fernandez-Capetillo O. (2008). Atr signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 22, 297-302.
149. Tomasini R., Tsuchihara K., Wilhelm M., Fujitani M., Rufini A., Cheung C.C., Khan F., Itie-Youten A., Wakeham A., Tsao M.S., Iovanna J.L., Squire J., Jurisica I., Kaplan D., Melino G., Jurisicova A. and Mak T.W. (2008). Tap73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22, 2677-2691.
150. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., Hee Park S., Thompson T., Karsenty G., Bradley A. and Donehower L.A. (2002). P53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53.
151. van Steensel B., Smogorzewska A. and de Lange T. (1998). Trf2 protects human telomeres from end-to-end fusions. Cell 92, 401-413.
152. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R. and Jacks T. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665.
153. Waga S., Hannon G.J., Beach D. and Stillman B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with pcna. Nature 369, 574-578.
154. Wahl G.M. and Carr A.M. (2001). The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat. Cell Biol. 3, E277-286.
155. Wang W., Chen J.X., Liao R., Deng Q., Zhou J.J., Huang S. and Sun P. (2002). Sequential activation of the mek-extracellular signalregulated kinase and mkk3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol. Cell. Biol. 22, 3389-3403.
156. Wang Y., Blandino G., Oren M. and Givol D. (1998). Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 17, 1923-1930.
157. Wang Y., Blandino G. and Givol D. (1999). Induced p21waf expression in h1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene 18, 2643-2649.
158. Wei S. and Sedivy J.M. (1999). Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic ha-ras in normal human fibroblasts. Cancer Res. 59, 1539-1543.
159. Wei W., Hemmer R.M. and Sedivy J.M. (2001). Role of p14(arf) in replicative and induced senescence of human fibroblasts. Mol. Cell Biol. 21, 6748-6757.
160. Whitmarsh A.J., Yang S.H., Su M.S., Sharrocks A.D. and Davis R.J. (1997). Role of p38 and jnk mitogen-activated protein kinases in the activation of ternary complex factors. Mol. Cell. Biol. 17, 2360-2371.
161. Xu D., Wang Q., Gruber A., Bjorkholm M., Chen Z., Zaid A., Selivanova G., Peterson C., Wiman K.G. and Pisa P. (2000). Downregulation of telomerase reverse transcriptase mrna expression by wild type p53 in human tumor cells. Oncogene 19, 5123-5133.
162. Xu H.J., Zhou Y., Ji W., Perng G.S., Kruzelock R., Kong C.T., Bast R.C., Mills G.B., Li J. and Hu S.X. (1997). Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15, 2589-2596.
163. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C. and Lowe S.W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
164. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D. and McKeon F. (1998). P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 2, 305-316.
165. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C. and McKeon F. (1999). P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714-718.
166. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F. and Caput D. (2000). P73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99-103.
167. Yoon D.Y., Buchler P., Saarikoski S.T., Hines O.J., Reber H.A. and Hankinson O. (2001). Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem. Biophys Res. Commun. 288, 882-886.
168. Zawel L., Yu J., Torrance C.J., Markowitz S., Kinzler K.W., Vogelstein B. and Zhou S. (2002). Dec1 is a downstream target of tgf-beta with sequence-specific transcriptional repressor activities. Proc. Natl. Acad. Sci. USA 99, 2848-2853.
169. Zhang Y. and Xiong Y. (2001). Control of p53 ubiquitination and nuclear export by mdm2 and arf. Cell Growth Differ. 12, 175-186.
170. Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman W.H., Tom E., Mack D.H. and Levine A.J. (2000). Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981-993.
171. Zhu J., Jiang J., Zhou W. and Chen X. (1998). The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58, 5061-5065.